2X Blend: Tesamorelin 10mg + Ipamorelin 2mg

What is 2X Blend: Tesamorelin (10mg) + Ipamorelin (2mg)?

2X Blend: Tesamorelin (10mg) + Ipamorelin (2mg) is a two-peptide research blend commonly used to study the endocrine and growth hormone pathways. In laboratory settings, these peptides support experimental designs exploring receptor-driven signaling, pathway interactions, and downstream biomarker readouts in controlled models.

Tesamorelin is a stabilized GHRH (growth hormone–releasing hormone) analog, while Ipamorelin is a ghrelin (GHS-R) receptor agonist peptide often included in growth hormone secretagogue research.

Product Specifications

CAS Numbers:

• Tesamorelin: 218949-48-5
• Ipamorelin: 170851-70-4

Peptide Sequences:

• Tesamorelin: Trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
• Ipamorelin: Aib–His-D-2Nal-D-Phe-Lys

Molecular Formulas: 

• Tesamorelin: C₂₂₁H₃₆₆N₇₂O₆₇S
• Ipamorelin: C₃₈H₄₉N₉O₅

Molecular Weights: 

• Tesamorelin: 5136 g/mol
• Ipamorelin: 711.9 g/mol

Synonyms:

• Tesamorelin: TH9507
• Ipamorelin: NNC 26-0161

Category: Peptides

• Subcategory: Muscle Growth & Performance Peptides
• Purity: ≥99% (use lot-specific COA for the exact value)
• Packaging Format: 1 vial (Tesamorelin (10mg) + Ipamorelin (2mg))
• Storage Conditions: Store at -20°C, avoid light exposure

Key Characteristics of 2X Blend: Tesamorelin (10mg) + Ipamorelin (2mg)

• Complementary Peptides: A blend of GHRH-analog (Tesamorelin) and GHS-R agonist (Ipamorelin) peptides, frequently used in growth-hormone pathway studies.
• Defined Sequences: Supported by CAS numbers and molecular structure records for reproducible experimental documentation.
• Reproducibility: Useful for controlled signaling studies where researchers track receptor-linked readouts and downstream biomarkers over time.
• Assay Work: Ideal for method development, pathway profiling, and comparative experiments where standardized materials are crucial.

How 2X Blend: Tesamorelin (10mg) + Ipamorelin (2mg) Supports Research

This peptide blend is used in research settings to investigate growth-hormone–related endocrine signaling. Tesamorelin, as a stabilized analog of human GHRH, engages the GHRH receptor pathway, while Ipamorelin, a selective growth hormone secretagogue, acts through the ghrelin/GHS receptor system. Together, they provide researchers with tools to explore receptor-mediated signaling and downstream experimental readouts in controlled models.

Research Applications & Usage Information

2X Blend: Tesamorelin (10mg) + Ipamorelin (2mg) is commonly used in research for:

• Endocrine Signaling Pathway Studies: Mapping receptor activation patterns and downstream biomarkers in experimental systems.
• Receptor Activity and Pathway Profiling: Comparative designs evaluating GHRH vs. GHS-R–linked signaling behavior.
• Gene/Protein Marker Workflows: Tracking changes in selected signaling markers after experimental exposure (model-dependent).
• Assay Development and Validation: Using defined peptide tools to benchmark sensitivity, repeatability, and measurement consistency.
• Mechanistic Studies: Research on growth hormone secretagogues, including ghrelin receptor agonist signaling.

Note: This material is intended for laboratory research use only. Study methods and models vary by institution and protocol.

Handling and Storage Recommendations

• Store at -20°C and protect from light (keep in original packaging or a light-limiting container).
• Avoid repeated freeze–thaw cycles.
• Keep the vial tightly closed and handle it using clean laboratory techniques to minimize contamination.
• Follow standard PPE practices and your facility’s chemical hygiene, labeling, and disposal procedures.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 16137828, Tesamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin.
2. National Center for Biotechnology Information. PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin.
3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
4. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490
5. Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25(2):59-65. doi:10.1016/j.ghir.2014.12.005